The OncoAlert Colloquium
SPOKEN IN YOUR LANGUAGE
The Sixth Annual OncoAlert Colloquium is a 100% virtual, one-week educational meeting highlighting the most important developments in oncology from the past year. Presentations are delivered by leading oncologists from around the world in a multidisciplinary format.
As a global oncology network, OncoAlert is committed to advancing cancer care through high-quality, accessible education tailored to the needs of diverse regions and audiences.
As an added bonus, The OncoAlert Colloquium is NOW AVAILABLE IN YOUR LANGUAGE! Watch this short 15-second video to learn how to access the content and hear the world’s top experts present the most important oncology findings of the year in your own language — Our way of making cutting-edge information easier and more accessible for colleagues around the world.
On Behalf of OncoAlert and our Partners at The European Society of Surgical Oncology, The European Society of Gynaecological Oncology, Multinational Association of Supportive Care in Cancer and The International Society of Geriatric Oncology we Welcome you to the 2026 Colloquium.
As a global oncology network, OncoAlert is committed to advancing cancer care through high-quality, accessible education tailored to the needs of diverse regions and audiences.
As an added bonus, The OncoAlert Colloquium is NOW AVAILABLE IN YOUR LANGUAGE! Watch this short 15-second video to learn how to access the content and hear the world’s top experts present the most important oncology findings of the year in your own language — Our way of making cutting-edge information easier and more accessible for colleagues around the world.
On Behalf of OncoAlert and our Partners at The European Society of Surgical Oncology, The European Society of Gynaecological Oncology, Multinational Association of Supportive Care in Cancer and The International Society of Geriatric Oncology we Welcome you to the 2026 Colloquium.
|
Bladder Cancer – Dr. Tom Powles
|
Kidney Cancer – Dr. Brian Rini
|
Prostate Cancer– Dr. Silke Gillessen
|
|
Urology Review– Drs. Murphy & Eapen
|
Diagnostics– Dr Juan Antonio Vallejo
|
GU Radiotherapy –Dr. Sean McBride
|
|
Advocacy– Salvo LaRosa (KCA)
|
How I Treat –Dr. Natalia Gandur
|
|
|
ER+ Metastatic - Dr. Erika Hamilton
|
HER2+ Metastatic– Dr. Stephanie Graff
|
Adv. Triple-Negative – Dr. Hope Rugo
|
|
Early Triple-Negative –Dr. Rebecca Dent
|
ER+ Early – Dr. Matteo Lambertini
|
HER2+ Early – Dr. Evandro de Azambuja
|
|
Pathology – Dr. Roberto Salgado
|
Surgical – Dr. Isabel Rubio
|
Radiotherapy – Dr. Icro Meattini
|
|
How I Treat – Dr. Lazar Popovic
|
|
Colon & Anal Cancer – Dr. Cathy Eng
|
GEJ & Liver Cancers – Dr. N. Hornstein
|
Pancreatic Cancer – Dr. Grainne O’Kane
|
|
Tumor-Agnostic – Dr. B. Westphalen
|
GI Radiotherapy– Dr. Nina Sanford
|
Upper GI Surgery– Dr. John Herrera Kok
|
|
Lower GI Surgery – Dr. Marco Inama
|
How I Treat – Dr. Erman Akkus
|
Patient Advocate– Ms. Allison Rosen
|
|
Cervical (Surg)–Dr. Nicolò Bizzarri
|
Cervical (Med)–Dr. Vanda Salutari
|
Endometrial (Surg)–Dr. A. Strojna
|
|
Endometrial (Med)–Dr. A. Ferrero
|
Ovarian (Surg)–Dr. Alejandra Martinez
|
Ovarian (Med)–Dr. Isabelle Ray-Coquard
|
|
Vaginal (Sure)–Dr. Christina Fotopoulou
|
Vulvar (Surg)–Dr. Giorgia Garganesse
|
Vaginal & Vulvar (Med)–Dr. C. Chargari
|
|
Patient Advocate: Ms. A. De Middelaer
|
|
Early NSCLC – Dr. Gilberto Lopes
|
Advanced NSCLC– Dr. Biagio Ricciuti
|
SCLC+ Mesothelioma– Dr. G. Mountzios
|
|
Diagnostics– Dr. Umberto Malapelle
|
Radiotherapy– Dr. Gerry Hanna
|
Patient Advocate– Ms. Jill Feldman
|
|
How I Treat – Dr. Ugur Ozkerim
|
|
Lymphoma – Dr. Jason Westin
|
Sarcoma – Dr Elise Nassif Haddad
|
|
Multiple Myeloma – Dr. Al Ola Abdallah
|
Leukemia – Dr. Fadi Haddad
|
|
Melanoma – Dr. Allison Betof Warner
|
Head & Neck – Dr. Pablo Jimenez
|
|
MASCC Guidelines– Dr. Alex Chan
|
Chemo Induced Nausea - Dr. H. Iihara
|
|
Geriatric Oncology - Dr. Kristen Haase
|
**The Colloquium is supported by AstraZeneca, Nuvalent, Pfizer and Roche, with all presentations made independently by the presenters, without any industry influence on the topics or content.